Citations

Mayo Clinic

Showing 10 of 108522 citations.

Momelotinib treatment‐emergent neuropathy: prevalence, risk factors and outcome in 100 patients with myelofibrosis
Abdelrahman, Ramy A., Begna, Kebede H. , Al‐Kali, Aref , Litzow, Mark R. , Pardanani, Animesh , Tefferi, Ayalew , Hogan, William J.

British Journal of Haematology | December 16, 2014 | Volume: 169 | Issue: 1 | Pages: 77-80

10.1111/bjh.13262 | PMID 25511866 Get It

SummaryMomelotinib (a JAK1 and JAK2 inhibitor) induces both anaemia and spleen responses in myelofibrosis (MF). Momelotinib treatment‐emergent peripheral neuropathy (TE‐PN) was documented in 44 (44%) of 100 MF patients treated at our institution; median time of TE‐PN onset was 32 weeks and duration 11 months. Improvement after drug dose reduction or discontinuation was documented in only two patients. TE‐PN was significantly associated with treatment response (P = 0·02) and longer survival (P = 0·048) but significance was lost during multivariate analysis that included treatment duration. TE‐PN did not correlate with initial or maximum momelotinib dose or previous treatment with JAK inhibitor or thalidomide.
Letter: clinical predictors of Clostridium difficile infection – advanced age and residential status are important factors for prediction and prevention – authors' reply
Pardi, Darrell S. , Shivashankar, Raina , Khanna, Sahil , Baddour, Larry M.

Alimentary Pharmacology & Therapeutics | December 16, 2014 | Volume: 41 | Issue: 2 | Pages: 233-233

10.1111/apt.13033 | PMID 25511771 Get It

Randomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in Patients With Advanced Pancreatic Cancer
Reddy, Shantan, Bahary, Nathan , Uronis, Hope E. , Sigal, Darren , Cohn, Allen Lee, Schelman, William R., Stephenson, Joe , Chiorean, E. Gabriela , Rosen, Peter J., Ulrich, Brian, Dragovich, Tomislav , Prete, Salvatore A. Del , Rarick, Mark U., Eng, Clarence, Kroll, Stew, Ryan, David P. , Reddy, Shantan G, Cohn, Allen L, Del Prete, Salvatore A, Rarick, Mark, Borad, Mitesh J.

Journal of Clinical Oncology | December 16, 2014 | Volume: 33 | Issue: 13 | Pages: 1475-1481

10.1200/jco.2014.55.7504 | PMID 25512461 Get It

Purpose TH-302 is an investigational hypoxia-activated prodrug that releases the DNA alkylator bromo-isophosphoramide mustard in hypoxic settings. This phase II study (NCT01144455) evaluated gemcitabine plus TH-302 in patients with previously untreated, locally advanced or metastatic pancreatic cancer. Patients and Methods Patients were randomly assigned 1:1:1 to gemcitabine (1,000 mg/m2), gemcitabine plus TH-302 240 mg/m2 (G+T240), or gemcitabine plus TH-302 340 mg/m2 (G+T340). Randomized crossover after progression on gemcitabine was allowed. The primary end point was progression-free survival (PFS). Secondary end points included overall survival (OS), tumor response, CA 19-9 response, and safety. Results Two hundred fourteen patients (77% with metastatic disease) were enrolled between June 2010 and July 2011. PFS was significantly longer with gemcitabine plus TH-302 (pooled combination arms) compared with gemcitabine alone (median PFS, 5.6 v 3.6 months, respectively; hazard ratio, 0.61; 95% CI, 0.43 to 0.87; P = .005; median PFS for metastatic disease, 5.1 v 3.4 months, respectively). Median PFS times for G+T240 and G+T340 were 5.6 and 6.0 months, respectively. Tumor response was 12%, 17%, and 26% in the gemcitabine, G+T240, and G+T340 arms, respectively (G+T340 v gemcitabine, P = .04). CA 19-9 decrease was greater with G+T340 versus gemcitabine (−5,398 v −549 U/mL, respectively; P = .008). Median OS times for gemcitabine, G+T240, and G+T340 were 6.9, 8.7, and 9.2 months, respectively (P = not significant). The most common adverse events (AEs) were fatigue, nausea, and peripheral edema (frequencies similar across arms). Skin and mucosal toxicities (2% grade 3) and myelosuppression (55% grade 3 or 4) were the most common TH-302–related AEs but were not associated with treatment discontinuation. Conclusion PFS, tumor response, and CA 19-9 response were significantly improved with G+TH-302. G+T340 is being investigated further in the phase III MAESTRO study (NCT01746979).
Implementation of physical activity programs after COPD hospitalizations
Benzo, Roberto , Wetzstein, Marnie M. , Neuenfeldt, Pamela, McEvoy, Charlene , Wetzstein, Marnie

Chronic Respiratory Disease | December 15, 2014 | Volume: 12 | Issue: 1 | Pages: 5-10

10.1177/1479972314562208 | PMID 25511306 Get It

Pulmonary rehabilitation (PR), following an acute exacerbation of chronic obstructive pulmonary disease (COPD), has been found effective in some studies in reducing readmission rates as and has recently been recommended by the PR guidelines. However, very recent reports suggested that PR is not feasible after a hospital admission for a COPD exacerbation. The objective of this study is to investigate the knowledge gap on the underlying reasons for nonparticipation in PR in the posthospitalization period. We qualitatively analyzed the responses of 531 patients hospitalized for a COPD exacerbation who were not interested in participating in either PR (home or center based) or physical activity monitoring program after being discharged from the hospital. The responses were coded thematically, and independent reviewers compiled the raw data into themes. The characteristics of the 531 subjects (45% male) who declined the intervention are as follows: age was 70 ± 10 years, mean forced expiratory volume in one second (FEV1%) predicted 40 ± 16, and age, dyspnea, and airflow obstruction index 6.0 ± 1.6 (scale 0–10). The themes for not attending include lack of interest (39%), the perception of “being too ill or frail or disabled” (24%), the perception of being “too busy or having too much to do” (11%), distance or the need of travel (11%), commitment issues (7%), comorbidities (6%), and lack of social support (2%). We identified barriers for PR or just physical activity programs after a hospitalization that may affect implementation of such programs. Implementing posthospitalizations program in COPD may require patient engagement and mindful and compassionate professionals who may individualize program components to focus specific deficits and particularly patients’ preferences.
Expression and prognostic impact of lncRNAs in acute myeloid leukemia
Garzon, Ramiro , Volinia, Stefano , Papaioannou, Dimitrios , Kohlschmidt, Jessica, Yan, Pearlly S. , Mrózek, Krzysztof , Bucci, Donna, Carroll, Andrew J. , Baer, Maria R. , Wetzler, Meir , Carter, Thomas H. , Powell, Bayard L., Kolitz, Jonathan E. , Moore, Joseph O., Eisfeld, Ann-Kathrin, Blachly, James S. , Blum, William , Stone, Richard M. , Marcucci, Guido , Byrd, John C. , Bloomfield, Clara D. , Byrd, John C. , Nicolet, Deedra , Eisfeld, Ann‐Kathrin , Caligiuri, Michael A. , Croce, Carlo Maria , Blachly, James , Byrd, John C

Proceedings of the National Academy of Sciences | December 15, 2014 | Volume: 111 | Issue: 52 | Pages: 18679-18684

10.1073/pnas.1422050112 | PMID 25512507 Get It

Significance Long noncoding RNAs (lncRNAs) are involved in numerous biological roles including epigenetic regulation, apoptosis, and cell cycle. Whereas lncRNAs contribute to epigenetic gene regulation, metastasis, and prognosis in solid tumors, their role in acute myeloid leukemia (AML) has not been hitherto reported. Here, we show that lncRNA expression profiles are associated with recurrent mutations, clinical features, and outcome in AML. A fraction of these lncRNAs may have a functional role in leukemogenesis. Furthermore, lncRNAs could be used as biomarkers for outcome in AML. The identification of patients likely to achieve complete remission with standard therapy alone, based on lncRNA expression, is a significant advance potentially sparing such patients from other toxicities and focusing investigational approaches on postremission studies.
Large-scale topology and the default mode network in the mouse connectome
Stafford, James M. , Jarrett, Benjamin R., Miranda-Domínguez, Óscar , Mills, Brian D. , Cain, Nicholas , Lahvis, Garet P. , Lattal, K. Matthew , Mitchell, Suzanne H. , David, Stephen V. , Fryer, John Denis , Fryer, John D., Mihalaş, Ştefan , Nigg, Joel T. , Fair, Damien A.

Proceedings of the National Academy of Sciences | December 15, 2014 | Volume: 111 | Issue: 52 | Pages: 18745-18750

10.1073/pnas.1404346111 | PMID 25512496 Get It

Significance Noninvasive brain imaging holds great promise for expanding our capabilities of treating human neurologic and psychiatric disorders. However, key limitations exist in human-only studies, and the ability to use animal models would greatly advance our understanding of human brain function. Mice offer sophisticated genetic and molecular methodology, but correlating these data to functional brain imaging in the mouse brain has remained a major hurdle. This study is the first, to our knowledge, to use whole-brain functional imaging to show large-scale functional architecture with structural correlates in the mouse. Perhaps more important is the finding of conservation in brain topology and default network among rodents and primates, thereby clearing the way for a bridge measurement between human and mouse models.
Perineural tumor spread to the muscle: An alternative for muscle metastasis?
Amrami, Kimberly K. , Howe, Benjamin M. , Spinner, Robert J. , Capek, Stepan

Clinical Anatomy | December 15, 2014 | Volume: 28 | Issue: 5 | Pages: 560-562

10.1002/ca.22485 | PMID 25511297 Get It

Lateral neck recurrence from papillary thyroid carcinoma: Predictive factors and prognostic significance
Giordano, Davide , Frasoldati, Andrea , Kasperbauer, Jan L. , Gabrielli, Enrico, Pernice, Carmine , Zini, Michele , Pedroni, Corrado, Cavuto, Silvio , Barbieri, Verter

The Laryngoscope | December 15, 2014 | Volume: 125 | Issue: 9 | Pages: 2226-2231

10.1002/lary.25094 | PMID 25510637 Get It

Objectives/HypothesisThe aim of this study was to identify any possible predictive factors of lateral neck recurrence in patients with papillary thyroid carcinoma with no ultrasonographic and/or cytological evidence of lymph node metastasis at time of diagnosis. The influence of lateral neck recurrence on survival was also investigated.Study DesignObservational retrospective study.MethodsRetrospective review of clinical records of 610 patients surgically treated for papillary thyroid carcinoma with clinically negative lymph nodes at the Otolaryngology Unit of the Arcispedale Santa Maria Nuova–IRCCS, Reggio Emilia, Italy, from January 1984 to December 2008.ResultsLateral neck recurrences were ipsilateral to the primary tumor in all cases and were associated with the occurrence of more aggressive histological variants and central neck metastasis. Lateral neck recurrences were more frequently observed in patients with distant metastases and were associated with a reduced disease‐specific survival.ConclusionLateral neck compartment ipsilateral to the tumor was the most common site of recurrence, with about half of cases appearing in the first 28 months of follow‐up. In patients with papillary thyroid carcinoma, detection of lateral neck metastases prior to first surgery is crucial to surgical planning. Aggressive histological variants and postsurgical evidence of lymph node metastasis from papillary thyroid carcinoma in central neck compartment are associated with a higher risk of lateral neck recurrence. In these patients, a closer postsurgical ultrasound surveillance of the lateral neck compartments seems worthwhile.Level of Evidence4. Laryngoscope, 125:2226–2231, 2015
Kinetic characterization of a cocaine hydrolase engineered from mouse butyrylcholinesterase
Chen, Xiabin , Huang, Xiaoqin , Geng, Liyi, Hou, Shurong , Zheng, Xirong, Brimijoin, Stephen , Zhan, Chang‐Guo , Liu, Xue , Zheng, Fang

Biochemical Journal | December 15, 2014 | Volume: 466 | Issue: 2 | Pages: 243-251

10.1042/bj20141266 | PMID 25486543 Get It

Mouse butyrylcholinesterase (mBChE) and an mBChE-based cocaine hydrolase (mCocH, i.e. the A199S/S227A/S287G/A328W/Y332G mutant) have been characterized for their catalytic activities against cocaine, i.e. naturally occurring (−)-cocaine, in comparison with the corresponding human BChE (hBChE) and an hBChE-based cocaine hydrolase (hCocH, i.e. the A199S/F227A/S287G/A328W/Y332G mutant). It has been demonstrated that mCocH and hCocH have improved the catalytic efficiency of mBChE and hBChE against (−)-cocaine by ~8- and ~2000-fold respectively, although the catalytic efficiencies of mCocH and hCocH against other substrates, including acetylcholine (ACh) and butyrylthiocholine (BTC), are close to those of the corresponding wild-type enzymes mBChE and hBChE. According to the kinetic data, the catalytic efficiency (kcat/KM) of mBChE against (−)-cocaine is comparable with that of hBChE, but the catalytic efficiency of mCocH against (−)-cocaine is remarkably lower than that of hCocH by ~250-fold. The remarkable difference in the catalytic activity between mCocH and hCocH is consistent with the difference between the enzyme–(−)-cocaine binding modes obtained from molecular modelling. Further, both mBChE and hBChE demonstrated substrate activation for all of the examined substrates [(−)-cocaine, ACh and BTC] at high concentrations, whereas both mCocH and hCocH showed substrate inhibition for all three substrates at high concentrations. The amino-acid mutations have remarkably converted substrate activation of the enzymes into substrate inhibition, implying that the rate-determining step of the reaction in mCocH and hCocH might be different from that in mBChE and hBChE.
Screening for Abdominal Aortic Aneurysm during Transthoracic Echocardiography in Patients with Significant Coronary Artery Disease
Lee, Sung Ho , Chang, Sung‐A , Jang, Shin Yi , Song, Young Bin , Park, Seung Woo , Gwon, Hyeon‐Cheol , Oh, Jae K. , Kim, Duk‐Kyung , Lee, Sang‐Chol , Song, Young Bin , Choi, Seung‐Hyuk

Yonsei Medical Journal | December 15, 2014 | Volume: 56 | Issue: 1 | Pages: 38

10.3349/ymj.2015.56.1.38 | PMID 25510745 Get It